Gene Research
Liver gene profiles signal patient response to hepatitis C therapy
Published in Hepatitis Weekly, July 4th, 2005
"Pegylated interferon (IFN)-alpha plus ribavirin is the most effective treatment of chronic hepatitis C but has unpleasant side effects and high costs. A large proportion of patients do not respond to therapy for reasons that are unclear," scientists writing in the journal Gastroenterology report.
"We used gene expression profiling to investigate the molecular basis for treatment failure. Expression profiling was performed on percutaneous needle liver biopsy specimens taken before therapy. Gene expression levels were compared among 15 nonresponder, 16 responder, and 20 normal...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-07-04)
More Articles from Hepatitis Weekly
- Adverse Drug Reaction
Patients with interferon-induced Graves disease fare better than others - Diagnostics
IgM anti-hepatitis C virus titers divulge the threat of acute hepatitis - Hepatocellular Carcinoma
Murine liver tumors respond to combined suicide-cytokine gene therapy - Vaccine Development
Immunostimulatory adjuvant may be key to hepatitis C vaccine efficacy - Vaccine Development
Oligonucleotide prototype boosts immunological response to hepatitis B vaccine - Addiction Medicine
MELD scores are superior predictors of alcoholic hepatitis related mortality - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
